Company · AZN (Nasdaq and LSE)
AstraZeneca
Pharmaceutical Preparations
Key figures
- Revenue, 2025
- $58.74B
- Employees
- 70,600
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Institutional holders
- 1,498 at 30 Jun 2026 (1,385 the quarter before)
- SEC number
- 901832
- LEI
- PY6ZZQWO2IZFZC3IOL08
Source: SEC EDGAR filings and company facts, SEC Form 13F; checked 27 Oct 2026
About
AstraZeneca is a British-Swedish pharmaceutical company in pharmaceutical industry, headquartered in Cambridge, founded in 1913.
Source: Wikidata
Latest filings
22 Oct 2026
6-K ULTOMIRIS APPROVED IN US IN IGAN
5 Oct 2026
6-K ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT
2 Oct 2026
6-K AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY
1 Oct 2026
6-K ADMISSION OF FURTHER SECURITIES TO TRADING
1 Oct 2026
6-K TOTAL VOTING RIGHTS
Source: SEC EDGAR
With a free account
A free account opens 10 full pages a month and lets you follow this page: 12 quarters of figures, every filing and document, earnings call transcripts, holders and ownership changes, the Brain's cards and graph, exports to Excel.
Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.